MultiplAI combines next-generation RNA sequencing and artificial intelligence to develop an accessible, affordable and highly accurate blood test to screen for the world’s biggest killer

LONDON, UK, Mar. 2, 2023 — MultiplAI Health, a techbio diagnostics company developing universal precision screening technology for cardiovascular and other complex diseases, has raised US$2.7 million in seed investment. The investment, led by SF500, Zentynel and Time Partners, is being directed towards achieving technical validation of their proprietary RNA-based, AI-driven product, building the MultiplAI team and expanding its operations and partnerships in the US.

MultiplAI Health is combining genomic data and artificial intelligence to develop a simple, accessible whole blood test – known as a liquid biopsy – that gives a highly accurate assessment of an individual’s risk of cardiovascular and other complex diseases at a fraction of the cost of today’s screening options. The universal test will enable healthcare professionals to identify cardiovascular risks before symptoms start to appear and enables people to progressively track and manage their CVD risk from an early age.

Cardiovascular disease (CVD) is the world’s biggest killer, accounting for almost a third (18 million) of all global deaths annually and the largest burden on healthcare systems. Global spending on cardiovascular disease is expected to exceed US $1 trillion by 2035.

“80% of CVD-related deaths could be avoided with updated screening practices, like in cancer, where liquid biopsy is already being used to detect the disease earlier and save lives,” said Santiago Miruka, cardiologist, co-founder and CEO of MultplAI Health.

MultiplAI Health launched in the UK in 2020, with the support of startup creation engine Illumina Accelerator Cambridge run by genomic sequencing specialists Illumina. Since then, the company has launched several clinical studies in the UK and Argentina, and is now opening operations in the United States, a country where almost half (48%) of all adults have some form of cardiovascular disease, and where the company is eyeing opportunities with its liquid biopsy to enter the global screening market, valued at US $211 billion in 2021 and estimated to more than double within the next five years.

“In much the same way as the advent of the internet enabled e-commerce companies to leverage vast amounts of data on consumer habits and behaviours, the giant steps made over the last decade in genomics, next generation sequencing technology and AI are enabling companies like ours to digitize biology, find meaning in the huge richness of molecular data and ultimately improve human health,” said Mark Ramondt, Co-founder/CFO/COO of MultiplAI Health. “We’re delighted to see such investor
confidence at this stage as we work towards launching our first products through partners in the US,” he added.

“Since MultiplAI became one of our first startups exploring how to harness genomics applications to improve healthcare, the company has rapidly implemented its plans to consolidate its exciting technology and build an amazing team internally and externally,” said Zentynel Managing Partner, Cristián Hernández.

“MultiplAI is part of an exciting new generation of life science companies working at the
interface of technology and biology to unlock massive amounts of genomic and molecular
information on the state of an individual’s health that hasn’t been analysed before,” said
Francisco Buchara, CEO of SF500.

“What MultiplAI is doing to develop universally accessible preventative screening for
complex diseases has the potential radically to improve the healthspan of millions of
people who currently lack local access to appropriate healthcare services,” said Time
Partners’ COO, Crispin Payne.

About MultiplAI Health
MultiplAI Health is a techbio diagnostics company developing screening technology to transform how cardiovascular diseases are diagnosed. Combining next-generation RNA sequencing and artificial intelligence, MultiplAI’s blood test is able to give the most complete and accurate disease risk analysis available today, at a fraction of the cost of current screening tools.

MultiplAI Health is based in London, UK, with clinical and lab operations in Cambridge, UK, and Buenos Aires, Argentina. For more information, please visit multiplaihealth.com.

About Zentynel
Zentynel is a venture capital fund with an investment focus on life sciences companies with high growth potential to address the world’s greatest health and food challenges.

Zentynel arose from the convergence of Fundacion Ciencia Vida and Venturance Alternative Assets. For more information, please visit zentynel.com/en.

About SF500
SF500 is a joint initiative of Bioceres and the Government of the Province of Santa Fe in Argentina that seeks to facilitate the emergence of 500 life science startups over the next decade. For more information, please visit sf500.com.ar/en.

About Time Partners
Time Partners is the investment advisor to Time Boost Capital, a UK £30 million genomics venture fund with investors including LifeArc, Illumina, and Illumina Ventures, created to fund genomics startups for graduates of Illumina Accelerator Cambridge, a company creation engine that focuses on harnessing genomics applications to improve human health, including novel therapeutics, diagnostics, synthetic biology, research tools, and agriculture. For more information, please visit time-partners.com.

#

Media Contact:
Steven Ramondt
MultiplAI Health
Tel/ Whatsapp: +44 (0) 745 330 3480
[email protected]

Investor Contact:
Mark Ramondt
MultiplAI Health
Tel/ Whatsapp: +44 (0) 784 984 515
[email protected]